Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Journal of Alzheimer'S Disease : JAD
|
February 19, 2016
AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics
Susanna Eketjäll, Juliette Janson, Karin Kaspersson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Nicolo Foppa Pedretti, Yashmin Karten, Yi Zhang, et al.
Journal of Attention Disorders
|
November 18, 2011
A randomized, double-blind, crossover comparison of MK-0929 and placebo in the treatment of adults with ADHD
Anna Rivkin, Robert C Alexander, Jennifer Knighton, et al.
Journal of Clinical Pharmacology
|
June 16, 2017
BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides
Kei Sakamoto, Shunji Matsuki, Kyoko Matsuguma, et al.
Journal of Alzheimer'S Disease : JAD
|
October 22, 2016
AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease
Gvido Cebers, Robert C Alexander, Samantha Budd Haeberlein, et al.
Journal of Psychopharmacology (Oxford, England)
|
February 15, 2013
Combined NK₁ antagonism and serotonin reuptake inhibition: effects on emotional processing in humans
Catherine J Harmer, Gerry R Dawson, Colin T Dourish, et al.
Plos One
|
February 18, 2010
Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections
Enrico Domenici, David R Willé, Federica Tozzi, et al.
The Lancet. Neurology
|
June 19, 2021
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial
Daniel K Burns, Robert C Alexander, Kathleen A Welsh-Bohmer, et al.
The Lancet. Neurology
|
February 21, 2026
A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA
Eric M Reiman, Robert C Alexander, Jessica B Langbaum, et al.
The Lancet. Neurology
|
January 24, 2026
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1<sup>Glu280Ala</sup> mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial
Pierre N Tariot, Francisco S Lopera, Silvia Ríos-Romenets, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Journal of Alzheimer'S Disease : JAD
|
February 19, 2016
AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics
Susanna Eketjäll, Juliette Janson, Karin Kaspersson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Nicolo Foppa Pedretti, Yashmin Karten, Yi Zhang, et al.
Journal of Attention Disorders
|
November 18, 2011
A randomized, double-blind, crossover comparison of MK-0929 and placebo in the treatment of adults with ADHD
Anna Rivkin, Robert C Alexander, Jennifer Knighton, et al.
Journal of Clinical Pharmacology
|
June 16, 2017
BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides
Kei Sakamoto, Shunji Matsuki, Kyoko Matsuguma, et al.
Journal of Alzheimer'S Disease : JAD
|
October 22, 2016
AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease
Gvido Cebers, Robert C Alexander, Samantha Budd Haeberlein, et al.
Journal of Psychopharmacology (Oxford, England)
|
February 15, 2013
Combined NK₁ antagonism and serotonin reuptake inhibition: effects on emotional processing in humans
Catherine J Harmer, Gerry R Dawson, Colin T Dourish, et al.
Plos One
|
February 18, 2010
Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections
Enrico Domenici, David R Willé, Federica Tozzi, et al.
The Lancet. Neurology
|
June 19, 2021
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial
Daniel K Burns, Robert C Alexander, Kathleen A Welsh-Bohmer, et al.
The Lancet. Neurology
|
February 21, 2026
A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA
Eric M Reiman, Robert C Alexander, Jessica B Langbaum, et al.
The Lancet. Neurology
|
January 24, 2026
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1<sup>Glu280Ala</sup> mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial
Pierre N Tariot, Francisco S Lopera, Silvia Ríos-Romenets, et al.
Page
of 2